This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04857/identifier/chemspider/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB04857/identifier/pubchem-compound/
n6http://linked.opendata.cz/resource/drugbank/drug/DB04857/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/drug/DB04857/identifier/kegg-drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04857/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB04857
rdf:type
n3:Drug
n3:description
Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K. In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.
n3:generalReferences
# Zhu M, Whigan DB, Chang SY, Dockens RC: Disposition and Metabolism of [14C]Brasofensine in Rats, Monkeys and Humans. Drug Metab Dispos. 2007 Oct 1;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17908924 # Johnston TH, Brotchie JM: Drugs in development for Parkinson's disease. Curr Opin Investig Drugs. 2004 Jul;5(7):720-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15298067 # Frackiewicz EJ, Jhee SS, Shiovitz TM, Webster J, Topham C, Dockens RC, Whigan D, Salazar DE, Cutler NR: Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. Ann Pharmacother. 2002 Feb;36(2):225-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11847938
n3:group
investigational
n3:halfLife
Plasma terminal elimination half-lives were ~2 hr in rats, ~4 hr in monkeys, but ~24 hr in humans.
n3:indication
For the treatment of Parkinson's Disease.
owl:sameAs
n13:DB04857
dcterms:title
Brasofensine
adms:identifier
n6:3846334 n7:D03153 n8:9554198 n9:7832208 n10:DB04857
n3:mechanismOfAction
When the neurotransmitter dopamine is released into the synaptic cleft, brasofensine prevents it from entering back into the source nerve cell, thereby allowing a longer period of synaptic activity.
n3:synonym
NS-2214
n3:IUPAC-Name
n4:271B5A2A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5A30-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5A2F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5A2C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5A2D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5A2E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5A28-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5A29-363D-11E5-9242-09173F13E4C5 n4:271B5A26-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5A27-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5A36-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5A37-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5A31-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5A32-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5A34-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5A33-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5A35-363D-11E5-9242-09173F13E4C5
n3:absorption
Brasofensine is rapidly absorbed after oral administration in rats and monkeys, with peak plasma concentrations occurring 0.5-1 hr, but 3-8 hr for brasofensine in humans.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
171655-91-7
n3:Bioavailability
n4:271B5A3B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5A3D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5A3E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5A3A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5A39-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5A3C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5A2B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5A38-363D-11E5-9242-09173F13E4C5